Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®

mAbs

Volumn 9, Issue 1, 2017, Pages 127-139

  Magnenat, Laurent ^a   Palmese, Angelo ^b   Fremaux, Christèle ^a   D'Amici, Fabio ^b   Terlizzese, Mariagrazia ^b   Rossi, Mara ^b   Chevalet, Laurent ^c  

^a Merck Biosimilars   (Switzerland)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Analytical and Pharmaceutical Development   (Switzerland)

Author keywords

adalimumab; analytical similarity; biosimilars; FcR; Humira ; MSB11022; TNF

Indexed keywords

ADALIMUMAB; BIOSIMILAR AGENT; COMPLEMENT COMPONENT C1Q; DISULFIDE; FC RECEPTOR; IMMUNOGLOBULIN G1; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ARTICLE; BIOASSAY; CIRCULAR DICHROISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIGHT CHAIN; MOLECULAR WEIGHT; PEPTIDE MAPPING; PHYSICOCHEMICAL MODEL; PROTEIN TERTIARY STRUCTURE; SURFACE PLASMON RESONANCE; TANDEM MASS SPECTROMETRY; THERMOSTABILITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; CHEMISTRY;

ADALIMUMAB; ANIMALS; ANTIRHEUMATIC AGENTS; BIOSIMILAR PHARMACEUTICALS; HUMANS;

EID: 85008931504     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1259046     Document Type: Article

References (28)

1. U.S. Food and Drug Administration. FDA is a biological product? [accessed 2016 Dec 21] http://www.fda.gov/AboutFDA/Transparency/Basics/ucm194516.html
2. Jung SK, Lee KH, Jeon JW, Lee JW, Kwon BO, Kim YJ, Bae JS, Kim DI, Lee SY, Chang SJ. Physicochemical characterization of Remsima. mAbs 2014;61163-1173; PMID:25517302; http://dx.doi.org/10.4161/mabs.32221
3. Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonem E, Ho K, et al. Biosimilars:what clinicians should know. Blood 2012;120:5111-5117; PMID:23093622; http://dx.doi.org/10.1182/blood-2012-04-425744
4. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 2012; 7:S57-S67; PMID:22249658; http://dx.doi.org/10.1007/s11523-011-0196-3
5. McCamish M, Woollett G. Worldwide experience with biosimilar development. MAbs 2011;3:209-217; PMID:21441787; http://dx.doi.org/10.4161/mabs.3.2.15005
6. Jha A, Upton A, Dunlop WC, Akehurst R. The budget impact of biosimilar infliximab (Remsima®) for the treatment of autoimmune diseases in five European countries. Adv Ther 2015;32:742-756; PMID:26343027; http://dx.doi.org/10.1007/s12325-015-0233-1
7. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars:the science of extrapolation. Blood 2014;124:3191-3196; PMID:25298038; http://dx.doi.org/10.1182/blood-2014-06-583617
8. AbbVie Inc. HUMIRA (adalimumab) injection, for subcutaneous use. 2016 Oct. [accessed 2016Dec21] http://www.rxabbvie.com/pdf/humira.pdf
9. AbbVie Inc. SPC Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen. 2016 Sep 23. [accessed 2016Dec21] https://www.medicines.org.uk/emc/medicine/21201
10. EMA. Summary of opinion (post authorisation):Humira (adalimumab). 2016 May 26. [accessed 2016Dec21] http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000481/WC500207152.pdf
11. Wen D, Vecchi MM, Gu S, Su L, Dolnikova J, Huang YM, Foley SF, Garber E, Pederson N, Meier W. Discovery and investigation of misincorporation of serine at asparagine positions in recombinant proteins expressed in Chinese hamster ovary cells. J Biol Chem 2009;284:32686-32694; PMID:19783658; http://dx.doi.org/10.1074/jbc.M109.059360
12. Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 2008;97:1414-1426; PMID:17721938; http://dx.doi.org/10.1002/jps.21104
13. Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun 2007;355:751-757; PMID:17321501; http://dx.doi.org/10.1016/j.bbrc.2007.02.042
14. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product. Guidance for Industry. [accessed 2016 Dec 21] http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf
15. Brorson K, Kendrick B. Perspectives on well-characterized biological proteins. In:Schiel JE, Davis Dl, Borisov OV, editors. State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization. Vol. 1. Monoclonal anti-body therapeutics:structure, function, and regulatory space. Washington, DC:ACS; 2014. p. 99-116; doi:10.1021/bk-2014-1176.ch004
16. Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-312; PMID:21478841; http://dx.doi.org/10.1038/nbt.1839
17. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Preksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 2011;48:860-866; PMID:21256596; http://dx.doi.org/10.1016/j.molimm.2010.12.009
18. Bertolotti-Ciarlet A, Wang W, Lownesa R, Pristatskya P, Fang Y, McKelvey T, Li Y, Li Y, Drummond J, Prueksarita T, et al. Impact of methionine oxidation on the binding of human IgG1 to FcRn and Fcγ receptors. Mol Immunol 2009;46:1878-1882; PMID:19269032; http://dx.doi.org/10.1016/j.molimm.2009.02.002
19. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281(33):23514-23524. Epub 2006 Jun 21; PMID:16793771; http://dx.doi.org/10.1074/jbc.M604292200
20. Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013; 57(12):6147-6153; PMID:24080653; http://dx.doi.org/10.1128/AAC.01285-13
21. Hyland E, Mant T, Vlachos P, Attkins N, Ullmann M, Roy S, Wagner V. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira® in healthy subjects. Br J Clin Pharmacol 2016;82:983-993; PMID:27285856; http://dx.doi.org/10.1111/bcp.13039
22. Visser J, Feuerstein I, Stangler T, Schmiederer T, Fritsch C, Schiestl M. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab. BioDrugs 2013; 27(5):495-507; PMID:23649935; http://dx.doi.org/10.1007/s40259-013-0036-3
23. Tebbey PW, Varga A, Naill M, Clewell J, Venema J. Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab). mAbs 2015;7(5):805-811; PMID:26230301; http://dx.doi.org/10.1080/19420862.2015.1073429
24. Terlizzese M, Simoni P, Antonetti F. In vitro comparison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP I) against TNF-alpha and TNF-beta. J Interferon Cytokine Res 1996; 16:1047-1053; PMID:8974008; https://dx.doi.org/10.1089/jir.1996.16.1047
25. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfield J, Sasso EH. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2009; 131:308-316; PMID:19188093; http://dx.doi.org/10.1016/j.clim.2009.01.002
26. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009; 45:124-31; PMID:19128982; http://dx.doi.org/10.1016/j.cyto.2008.11.008
27. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83:793-802; PMID:8521496; http://dx.doi.org/10.1016/0092-8674(95)90192-2
28. ICH harmonised tripartite guideline. Validation of analytical procedures:text and methodology Q2(R1). Current Step 4 version. 2005 Nov. [accessed 2016 Dec 21] http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf